Advanced RCC: nivolumab shows benefit even after progression

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • 13% of patients with advanced renal cell carcinoma (aRCC) treated beyond progression (TBP) with nivolumab (Opdivo) experiencing ≥30% further decrease in tumor burden.
  • Tumor burden reduction was observed in patients who initially responded and then progressed, and patients with stable disease or progressive disease as best overall response. 
  • Acceptable safety profile was maintained.

 

Why this matters

  • In November 2015, nivolumab became the first immune checkpoint inhibitor approved for aRCC. 
  • Immunotherapies are associated with tumor flare, with increased tumor burden or new lesions preceding clinical responses.
  • This may be mistaken for disease progression and lead to discontinuation.

Study design

  • 316 patients with aRCC who progressed on nivolumab were included.
  • Funding: Bristol-Myers Squibb and Ono Pharmaceutical Co. Ltd.

Key results

  • 153 were TBP patients, of which 20 patients showed ≥30% tumor burden reduction.
  • ≥30% tumor burden reduction was seen in 28% patients with complete or partial response, 6% with stable disease, and 14% with progressive disease as their best response before first progression.
  • 83% patients in TBP and 73% in non-TBP group experienced treatment-related adverse event.

Limitations

  • Rationale for TBP was not assessed.
  • Favorable disease characteristics of patients TBP may have overestimated the TBP benefit.